A specific inhibitor of the p38 mitogen activated protein kinase affects differentially the production of various cytokines by activated human T cells: Dependence on CD28 signaling and preferential inhibition of IL-10 production

被引:65
作者
Koprak, S [1 ]
Staruch, MJ [1 ]
Dumont, FJ [1 ]
机构
[1] Merck & Co Inc, Merck Sharp & Dohme Res Labs, Dept Immunol, Rahway, NJ 07065 USA
关键词
D O I
10.1006/cimm.1998.1448
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cytokine production upon T cell activation results from the integration of multiple signaling pathways from TCR/CD3 and from costimulatory molecules such as CD28. Among these pathways, the possible role of p38 mitogen activated protein kinase (MAPK) is the least understood. Here, we used a highly specific p38 MAPK inhibitor, the SB203580 compound, to examine the role of this enzyme in the induction of various cytokines in human T cells stimulated with anti-CD3 and anti-CD28 mAb together or in combination with PMA. Cytokine induction was monitored by ELISA and at the mRNA level. While SB203580 had little effect on IL-2 production and proliferation, it significantly reduced the production of several other cytokines, The secretion of IL-4, IL-5, IL-13, and TNF-alpha was inhibited by 20-50% with modes of T cell activation involving the CD28 pathway, whereas their mRNA expression was little affected. In contrast, IFN-gamma induction via CD28/PMA or CD3/CD28, but not CD3/PMA, was markedly diminished both at the protein and at the mRNA levels, Most interestingly, SB203580 also sup pressed IL-10 secretion and mRNA induction via CD28-dependent activation by 75-85% (IC50 similar to 0.2 mu M). Subset analysis suggested that this inhibition did not reflect a differential effect on T cell subsets. Therefore, p38 MAPK activity appears to contribute to cytokine production, mostly via CD28-dependent signaling, Moreover, IL-10 seems to rely more on this activity than other cytokines for its induction in T cells. (C) 1999 Academic Press.
引用
收藏
页码:87 / 95
页数:9
相关论文
共 42 条
[1]   Differential signaling by lymphocyte antigen receptors [J].
AlberolaIla, J ;
Takaki, S ;
Kerner, JD ;
Perlmutter, RM .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :125-154
[2]   The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumour necrosis factor [J].
Beyaert, R ;
Cuenda, A ;
VandenBerghe, W ;
Plaisance, S ;
Lee, JC ;
Haegeman, G ;
Cohen, P ;
Fiers, W .
EMBO JOURNAL, 1996, 15 (08) :1914-1923
[3]   The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation [J].
Chu, YF ;
Solski, PA ;
KhosraviFar, R ;
Der, CJ ;
Kelly, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (11) :6497-6501
[4]   The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs) [J].
Clerk, A ;
Sugden, PH .
FEBS LETTERS, 1998, 426 (01) :93-96
[6]  
Cohen SBA, 1997, J IMMUNOL, V158, P5596
[7]   COMPARISON OF LYMPHOKINE SECRETION AND MESSENGER-RNA EXPRESSION IN THE CD45RA(+) AND CD45RO(+) SUBSETS OF HUMAN PERIPHERAL-BLOOD CD4(+) AND CD8(+) LYMPHOCYTES [J].
CONLON, K ;
OSBORNE, J ;
MORIMOTO, C ;
ORTALDO, JR ;
YOUNG, HA .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (03) :644-648
[8]   T cell proliferation in response to interleukins 2 and 7 requires p38MAP kinase activation [J].
Crawley, JB ;
Rawlinson, L ;
Lali, FV ;
Page, TH ;
Saklatvala, J ;
Foxwell, BMJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (23) :15023-15027
[9]   SB-203580 IS A SPECIFIC INHIBITOR OF A MAP KINASE HOMOLOG WHICH IS STIMULATED BY CELLULAR STRESSES AND INTERLEUKIN-1 [J].
CUENDA, A ;
ROUSE, J ;
DOZA, YN ;
MEIER, R ;
COHEN, P ;
GALLAGHER, TF ;
YOUNG, PR ;
LEE, JC .
FEBS LETTERS, 1995, 364 (02) :229-233
[10]   The p38 mitogen-activated protein kinase pathway in activated and anergic Th1 cells [J].
DeSilva, DR ;
Jones, EA ;
Feeser, WS ;
Manos, EJ ;
Scherle, PA .
CELLULAR IMMUNOLOGY, 1997, 180 (02) :116-123